Janus 1 - Phase 3 study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo with Capecitabine in Subjects with Adenocarcenoma of Pancreas intolerant to first-line chemotherapy

  • Gurney, Howard (Primary Chief Investigator)
  • Butala, Radhika, (Chief Investigator)

Project: Research

Project Details

StatusActive
Effective start/end date1/10/14 → …